Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
GLP-1 receptor agonists have transformed type 2 diabetes and obesity treatment, but a rare vision safety signal deserves clinicians’ attention. Emerging evidence has raised concerns about a potential NAION risk with GLP-1 therapy, particularly with semaglutide (Ozempic, Rybelsus, and Wegovy). Non-arteritic anterior ischemic optic neuropathy (NAION) can cause sudden, usually …
Read More »GLP-1s and Vision Loss: What Prescribers Should Know About the Emerging NAION Signal
